Trials / Completed
CompletedNCT00079794
Iscar for Supplemental Care in Stage IV Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.
Detailed description
See Brief Summary
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iscar | |
| DRUG | mistletoe |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2004-03-16
- Last updated
- 2008-01-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00079794. Inclusion in this directory is not an endorsement.